Literature DB >> 24733854

Is there a role for vaccine-based therapy in recurrent glioblastoma?

Marc C Chamberlain1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24733854      PMCID： PMC3984562          DOI： 10.1093/neuonc/nou031

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  5 in total

1.  Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial".

Authors:  John H Sampson; Gordana Vlahovic
Journal:  Neuro Oncol       Date:  2014-01       Impact factor: 12.300

2.  Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.

Authors:  Orin Bloch; Courtney A Crane; Yelena Fuks; Rajwant Kaur; Manish K Aghi; Mitchel S Berger; Nicholas A Butowski; Susan M Chang; Jennifer L Clarke; Michael W McDermott; Michael D Prados; Andrew E Sloan; Jeffrey N Bruce; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2013-12-12       Impact factor: 12.300

3.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

4.  Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.

Authors:  Kathleen R Lamborn; W K Alfred Yung; Susan M Chang; Patrick Y Wen; Timothy F Cloughesy; Lisa M DeAngelis; H Ian Robins; Frank S Lieberman; Howard A Fine; Karen L Fink; Larry Junck; Lauren Abrey; Mark R Gilbert; Minesh Mehta; John G Kuhn; Kenneth D Aldape; Janelle Hibberts; Pamela M Peterson; Michael D Prados
Journal:  Neuro Oncol       Date:  2008-03-04       Impact factor: 12.300

5.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
  5 in total
  1 in total

Review 1.  Heat shock protein vaccines against glioblastoma: from bench to bedside.

Authors:  Leonel Ampie; Winward Choy; Jonathan B Lamano; Shayan Fakurnejad; Orin Bloch; Andrew T Parsa
Journal:  J Neurooncol       Date:  2015-06-21       Impact factor: 4.130
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.